A Receptor Named for the Wrong Intuition
The diagnosis is named after a TNF receptor, which makes an anti-TNF drug feel like the obvious next step — but the strongest trial evidence for this exact syndrome points to blocking a different cytokine entirely.
Elena V., a 31-year-old physical therapist, spent nearly a decade being told her recurrent fevers, migratory myalgia, and periorbital edema were “probably viral, probably stress” before a genetics referral, prompted by her episodes lasting consistently longer than a week at a time — unusual for the more common periodic fever syndromes — confirmed a heterozygous TNFRSF1A mutation and a diagnosis of TNF receptor-associated periodic syndrome. She was relieved to finally have a name for it, and immediately asked whether that meant a TNF-blocking drug, since that was the receptor the genetic report described as defective.
That question turns out to be the actual clinical pivot, not a simple factual follow-up. TRAPS is caused by a defect in TNF receptor shedding — mutant receptors fail to be cleaved from the cell surface and release into circulation the way they normally would, which sounds, on its face, like exactly the kind of problem a TNF-blocking drug should fix directly. But the disease's actual downstream biology runs mostly through inflammasome activation and IL-1 release, not through unopposed TNF signaling as such — which is why the CLUSTER trial (De Benedetti et al., NEJM 2018) tested and confirmed canakinumab's efficacy in TRAPS specifically, alongside FMF and HIDS/MKD, while separate case literature on anti-TNF agents in TRAPS describes a more mixed picture, including reports of patients whose symptoms did not fully resolve or, in some cases, appeared to worsen on TNF blockade. Elena's attacks currently run four to eight times a year, each lasting seven to fourteen days, disrupting both her work schedule and, increasingly, the trust she has in her own body between episodes. Between attacks she is entirely well — no baseline joint disease, no chronic renal impairment, no proteinuria on annual screening — and has no other family members with a confirmed diagnosis, though she now recalls an aunt who “was always getting mystery fevers” and was never formally worked up. That otherwise-clean baseline is part of why the diagnosis, once it finally arrived, felt to her less like an explanation and more like a label for something that had already been quietly organizing her life around unpredictable weeks she could never fully plan past.
Genetics-confirmed diagnosis, first biologic decision
I want to say plainly what she asked me directly: doesn't a TNF-receptor defect call for a TNF-blocking drug? Etanercept has real published experience in TRAPS, and treating the named mechanism seems like the natural first move rather than reaching past it for something else.
The mechanism is more indirect than the name suggests. The actual defect is in receptor shedding, but the clinical attacks are driven mostly downstream, through inflammasome activation and IL-1 release — which is exactly why the CLUSTER trial tested canakinumab in TRAPS specifically, alongside FMF and HIDS/MKD, and found it effective. The anti-TNF case literature is genuinely more mixed — some patients do reasonably well, but others don't achieve full control, and there are reports of symptoms not improving or even worsening on TNF blockade.
I understand why the name points toward etanercept — it pointed the same way to me the first time I managed a TRAPS patient. But the trial evidence we actually have doesn't follow the receptor's name; it follows the downstream biology, and that's canakinumab.
I don't think this has to be a permanent either-or choice, just a sequencing one. Start with canakinumab, the drug with the direct randomized trial evidence in TRAPS specifically — not a mechanistic inference, an actual outcome. If it doesn't fully control her attacks, etanercept remains a reasonable second-line option, and we'd have a specific, pre-agreed reason to reach for it rather than defaulting there first on the strength of the syndrome's name alone.
That also gives her a concrete answer to the question she actually asked: not “no, the TNF drug is wrong,” but “we're starting with the better-evidenced option, and the one you asked about stays available if we need it.”
Agreed: canakinumab started, with attack frequency and duration tracked over the next two treatment cycles as the measure of response — the rheumatologist's trial-evidence argument carried the decision once Elena's own question about anti-TNF therapy was answered directly rather than deferred.
Etanercept explicitly named and documented as the second-line plan if canakinumab doesn't achieve adequate control, so the next decision — if one is needed — doesn't start from scratch.